Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences

Executive Summary

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.

You may also be interested in...



Lucira Health’s Unexpected Sprint To A First-Of-Its-Kind EUA From FDA: The Inside Story

Lucira Health executive VP Kelly Brezoczky explains in this Medtech Insight case study how the company shifted gears from making a test for influenza A and B to quickly developing one that detected SARS-CoV-2. The result was the company’s COVID-19 All-In-One Test Kit, an at-home prescription molecular diagnostic test that was the first of its type to hit the market when the US FDA granted it emergency use authorization last November.

Ellume CEO Ponders Future Of Company’s Rapid COVID-19 Antigen Test

The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.

Analytica Announced Bold Expansion Of Its Pelvic Biofeedback Device

Analytica formed a joint venture with Chinese partners to distribute its PeriCoach system and take advantage of the large Asian urinary incontinence market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel